Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea. (NCT02963597), a randomized na study. The primary outcome is Pulmonary Artery Systolic Pressure..

2. Clinical Question

The study also planned to assess functional parameters, biomarkers, and echocardiographic parameters. Listed secondary outcomes include the 6 Minute Walk Test, NT-proBNP, length of stay, blood oxygenation, heart failure symptoms, fluid retention, and E/e' as an assumption of LVEDP. These outcomes cover different aspects of clinical status, but their presence in the record does not establish that results were posted for them.

3. Trial Design

This was a randomized, single-masked, parallel-group pilot study. Its official title describes it as a two center study. The registry lists enrollment of 21 and a completed status. The study start date is 2016-10-01, and the primary completion is recorded as 2017-08.

The two groups differed in whether Auto-PAP was added to standard medical therapy. Group A received standard medical therapy plus AirSense™ 10 AutoSet for 48hrs; Group B received standard medical therapy only. The registry identifies the allocation as randomized, but does not report how the random sequence was generated, whether allocation was concealed, or how participants were assigned. The masking field says single, but which people were masked is not reported in the registry record.

The primary endpoint was pulmonary artery systolic pressure in mmHg, summarized as a mean with a 95% confidence interval. The measurement description specifies transthoracic echocardiography on admission and 48 hours after enrollment, while the endpoint timeframe is 48 hours. The record does not specify whether the primary comparison concerned the 48-hour value alone, change from admission, or a model incorporating both measurements. That distinction matters because each approach answers a somewhat different statistical question.

The study is identified as a pilot, but the reason for choosing its enrollment target, any formal sample-size justification, and the intended precision of the endpoint estimate are not reported in the registry record. The record lists nine outcome measures and no analyses. It does not identify a full statistical analysis plan, an analysis population, or an approach to missing measurements. These omissions limit what can be inferred about how the completed study was intended to turn measurements into estimates and comparisons.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Patients pulmonary artery systolic pressures were measured by transthoracic echocardiography (TTE) on admission and 48 hours after enrollment.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Pulmonary Artery Systolic Pressure., measured over 48 hours.

Pulmonary artery systolic pressure is a continuous measurement reported in mmHg. In this study it was assessed by transthoracic echocardiography on admission and 48 hours after enrollment. The registry describes the primary endpoint as a mean with a 95% confidence interval and gives 48 hours as its timeframe.

As a general statistical matter, a continuous endpoint can preserve information about the range of measured values rather than reducing participants to broad categories. A group mean describes the center of the observed measurements, while a confidence interval communicates uncertainty about the estimate. The interval is not a range that necessarily contains most individual participants’ measurements; it is an expression of uncertainty about the estimated quantity under the analysis method.

The endpoint is relevant to the study’s stated objective of evaluating the effect of PAP therapy on pulmonary arterial pressures in acute decompensated heart failure with obstructive sleep apnea. However, its meaning depends on how the comparison is defined. A comparison of 48-hour measurements, a comparison of changes from admission, and an adjusted comparison accounting for baseline values are not interchangeable. The registry record does not specify which estimand or model was used.

No primary endpoint mean, confidence interval, or treatment comparison is reported in the registry record. Consequently, neither the magnitude nor precision of the primary endpoint estimate can be characterized from the information available in this record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies a randomized parallel-group design and a continuous primary endpoint. It describes the endpoint summary as a mean with a 95% confidence interval. However, it does not report the statistical model, the exact contrast, or the method used to calculate the confidence interval. The discussion below explains relevant concepts generally; it does not identify methods used in this trial unless the registry record explicitly says so.

What does a mean describe?

For a continuous measurement, the mean is the arithmetic average of observed values in the analysis group. It is one way to describe the center of a distribution. Its usefulness depends on the shape of the data and on whether a small number of unusually high or low values have a substantial influence. A mean alone does not describe the full spread or shape of individual measurements. The registry does not report a standard deviation, median, range, or other distributional summary for the primary endpoint.

The study’s endpoint description names a mean and a 95% confidence interval. A confidence interval is an interval estimate built from the observed data and a statistical procedure. In general, its width reflects both the variability in the data and the amount of information available for estimating the target quantity. A narrower interval indicates greater precision under the method’s assumptions; a wider interval indicates greater uncertainty. A confidence interval is not a guarantee that the true value lies within the particular interval, nor is it a range intended to contain a fixed proportion of individual measurements.

What comparison could the endpoint represent?

The registry describes measurements at admission and 48 hours after enrollment, and lists 48 hours as the primary endpoint timeframe. A statistical analysis must define what group contrast it estimates. One possible approach would compare the group means at 48 hours. Another would compare within-participant changes from admission. A third could model the 48-hour measurement while accounting for the admission value. These approaches can yield different estimates and answer different questions, especially if groups differ at baseline or if measurements are missing. The registry record does not report which approach was used.

For an interpretable treatment comparison, an estimate would generally identify the groups being contrasted and the scale of the contrast, such as a difference in means. The registry record does not report the primary contrast estimate. No new estimate can be reconstructed from the endpoint description alone, and no calculation is made.

Why does the analysis population matter?

Random allocation defines the intended comparison, but an analysis also needs to state which participants and measurements are included. An analysis of everyone randomized, an analysis of participants who received the assigned intervention, and an analysis limited to those with available measurements can differ. These general approaches have different strengths and potential biases. The registry record does not specify the primary analysis population or say how departures from the assigned intervention were handled.

Endpoint-specific denominators also matter. Enrollment is a study-level figure; it does not show how many participants had a usable measurement at the primary assessment. A denominator can vary across outcomes when measurements are unavailable or excluded. The registry record does not report the primary endpoint denominator, exclusions, or reasons for missing measurements.

What does randomization contribute?

Randomization is intended to make treatment assignment independent of measured and unmeasured baseline characteristics on average. This supports a causal comparison when the trial is conducted and analyzed appropriately. It does not ensure that every characteristic is balanced in a particular trial, and chance differences can remain, especially in a pilot study. The registry record identifies randomized allocation but does not report sequence generation, allocation concealment, baseline characteristics, or the method of analysis. Therefore, the design label alone does not establish how well the intended comparison was implemented.

How should statistical significance be read?

In general, a p-value measures how incompatible the observed data are with a specified null model, under the assumptions of the test. It does not measure the probability that the null hypothesis is true, the size of an effect, or its clinical importance. A p-value cannot replace an estimate and confidence interval, which convey the scale and precision of a contrast. The registry record does not report a primary p-value, and no significance conclusion can be drawn from the record.

The sample-size assumptions describe a planning illustration based on the observed effect, with a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The stated effect to detect is a fraction of the observed effect. Such an illustration is a hypothetical planning exercise, not an observed trial outcome and not observed power. Its interpretation depends on the assumptions used, and it does not show that the study was designed around those assumptions. The registry record does not report the trial’s own sample-size justification. No specific planning estimate is described.

Why can variance assumptions matter?

For continuous outcomes, statistical methods typically rely on assumptions about the distribution of measurements or model errors. General approaches may be sensitive to skewness, influential observations, or unequal variability across groups. If count data or rates are analyzed, over-dispersion means that variability exceeds what a chosen model expects; ignoring it can make uncertainty estimates too small. That concept is not evidence that over-dispersion occurred in this trial, whose primary outcome is continuous. The registry record does not report diagnostic checks or model assumptions for the primary endpoint.

Overall, the record gives the endpoint type, measurement timing, and a summary format, but not enough detail to reproduce the analysis. The exact model, contrast, handling of baseline measurements, missing-data method, confidence-interval procedure, and any sensitivity analyses are not reported in the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The record lists nine outcome measures, including the primary pulmonary artery systolic pressure endpoint and secondary functional, biomarker, symptom, and echocardiographic measures. Considering multiple outcomes can increase the chance of observing at least one apparently notable result by chance if each is tested separately. General approaches to multiplicity include specifying one primary outcome, arranging outcomes in a testing hierarchy, or adjusting inference across a family of comparisons. The registry record does not report a multiplicity strategy, a hierarchy among outcomes, or which comparisons were intended to support confirmatory conclusions.

The record lists no analyses. It does not report whether all listed outcomes were measured, whether each was analyzed, or whether any analyses were exploratory. The outcome list alone should not be read as evidence that results exist for every measure. Results for secondary outcomes are not reported in the registry record.

Missing data can affect both the size and interpretation of an estimate. In general, the effect depends on why measurements are missing and on the assumptions used to handle them. Possible analytic approaches include using available measurements, modeling outcomes under explicit missingness assumptions, or conducting sensitivity analyses. These are general options, not methods attributed to this study. The registry record does not report missing-data counts, reasons for missingness, imputation, or sensitivity analyses.

The analysis population and treatment of participants who did not follow assigned care are also not reported in the registry record. Without these details, readers cannot determine whether the posted analysis, if any, preserved the randomized comparison or how exclusions may have affected interpretation.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry reports adverse-event figures separately for Group A and Group B. For each group, 10 participants are listed as at risk for serious adverse events and 0 as affected. For each group, 10 are listed as at risk for other adverse events and 0 as affected. Deaths are listed as 0 in each group, and no serious adverse event terms are listed.

These are the recorded counts in the registry, not proof that no adverse events of any kind occurred outside the definitions, collection procedures, or reporting period used. The registry record does not report the adverse-event observation period, event definitions, monitoring procedures, or whether events were assessed systematically. It also does not explain how the adverse-event denominators relate to the overall enrollment figure.

A zero count in a group does not establish that the underlying risk is zero. In general, an observed count is subject to uncertainty, and the strength of a safety inference depends on the amount and duration of observation, event definitions, and completeness of reporting. The record does not provide uncertainty intervals for these counts or further detail on safety analyses. The figures should therefore be read as the adverse-event counts recorded, rather than as a definitive estimate of comparative safety.

12. What the Result Does, and Does Not, Mean

The registry record documents a randomized, parallel-group pilot study comparing standard medical therapy plus AirSense™ 10 AutoSet for 48hrs with standard medical therapy alone. Its primary endpoint was pulmonary artery systolic pressure, measured by transthoracic echocardiography, with a 48-hour timeframe. These design details establish the question the trial set out to address; they do not provide the answer.

The primary result itself is not reported in the registry record. The group means, 95% confidence intervals, endpoint-specific denominators, and a between-group estimate are absent. It is therefore not possible to describe the observed effect’s direction, size, or precision. The absence of a reported result must not be interpreted as evidence of no difference or as evidence of a difference.

The record’s status is completed, but completion does not establish that all planned outcomes were collected or analyzed. It lists functional parameters, biomarkers, length of stay, oxygenation, symptoms, fluid retention, and an echocardiographic measure among secondary outcomes. Their results are not reported in the registry record. The listed adverse-event counts show 0 serious events, 0 other events, and 0 deaths in each group among those recorded as at risk, but the observation period and event-collection details are not reported.

As a general principle, statistical estimates should be considered together with their uncertainty, analysis methods, and the context of the study design. Here, the lack of a posted primary estimate prevents that fuller interpretation. The record supports describing the trial’s planned comparison and available safety counts, but not a conclusion about treatment effectiveness, clinical importance, or comparative safety.

The findings also cannot establish whether any measured pressure change would translate into a change in other outcomes. The study summary says that functional, biomarker, and echocardiographic parameters were to be assessed, but the registry record does not report those results or any analysis connecting them to the primary endpoint. No clinical recommendation follows from the information recorded.

13. Why This Trial Matters Statistically

This trial raises a useful statistical question: how should a short-term, continuous physiological measurement be compared between randomized groups when measurements are planned at both admission and 48 hours? The answer depends on the target contrast. Comparing measurements at 48 hours, comparing changes from admission, and adjusting for baseline each defines a different analysis. The registry record identifies both measurement occasions but does not report which contrast was used.

The pilot designation is also important when reading a study’s purpose. Pilot studies can be used to explore feasibility, measurement procedures, and the variability of outcomes, as a general matter. Their estimates may be uncertain, and a small study may not provide precise estimates even when it is completed. The record does not report a formal sample-size justification or describe whether feasibility was a principal objective. Its pilot label alone does not establish the study’s intended statistical role.

The study also illustrates why a registry record’s outcome list and completed status should be distinguished from reported results. Nine outcome measures are listed, but no analyses are listed, and the primary numerical result is not reported. Without estimates and uncertainty intervals, readers cannot evaluate the magnitude or precision of the intended comparison. Without analysis details, they cannot assess how baseline measurements, missingness, and multiple outcomes were handled.

Finally, transparent reporting is essential to interpreting randomized comparisons. Allocation and masking labels are useful, but readers also need details about implementation, outcome availability, analysis populations, and statistical methods. For this study, several of those details are not reported in the registry record. The record therefore documents a clinically focused trial question and a defined design, while leaving the central quantitative result and key analytic choices unresolved.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for statistical interpretation is that the registry record does not report the primary endpoint result. No group means, confidence intervals, primary comparison estimate, or p-value are available in the record. The observed direction, magnitude, and precision of the endpoint cannot be assessed.

The measurement description and endpoint timeframe leave the analysis target unclear. Pulmonary artery systolic pressure was measured on admission and 48 hours after enrollment, but the registry record does not report whether the intended comparison used the 48-hour measurement, change from admission, or adjustment for baseline. The exact statistical model and confidence-interval method are also not reported.

Although enrollment is listed as 21, the primary endpoint denominator and analysis population are not reported. The record does not describe missing measurements, exclusions, adherence to the assigned intervention, or handling of participants without a 48-hour assessment. The adverse-event denominators do not resolve these endpoint-specific questions.

The design is described as randomized and single-masked, but the randomization procedure, allocation concealment, and identity of the masked party are not reported. The record also does not provide a statistical analysis plan, sample-size justification, multiplicity approach, or sensitivity analyses. The listed secondary outcomes have no analyses or results reported in the registry record.

The safety counts are limited by the absence of information on event definitions, observation period, and collection procedures. These limitations are specific to interpreting this record; they do not establish that a particular bias or reporting problem occurred. They mean that the available registry information is insufficient to reconstruct or fully evaluate the trial’s statistical analysis.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea. — NCT02963597.
• Registry record last updated 2020-03-30; status last verified 2019-03.
• Results first posted 2020-03-30.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry describes NCT02963597, a completed, randomized, single-masked, parallel-group pilot study sponsored by Albert Einstein Healthcare Network. Its official title identifies it as a two center study. Enrollment is listed as 21; the start date is 2016-10-01, and primary completion is recorded as 2017-08.

The study compared standard medical therapy plus AirSense™ 10 AutoSet for 48hrs with standard medical therapy alone in patients with decompensated heart failure and obstructive sleep apnea. The primary endpoint was mean pulmonary artery systolic pressure in mmHg at 48 hours, measured by transthoracic echocardiography on admission and 48 hours after enrollment. The primary endpoint result and statistical analyses are not reported in the registry record.

Nine outcome measures are listed. The adverse-event record lists 0 serious events, 0 other events, and 0 deaths in each group. Details on endpoint missingness, the analysis population, the statistical model, and the adverse-event observation period are not reported in the registry record.